2026

Argus (www.argusnetwork.co)

America

<h3 id="tldr">TLDR</h3>
<ul>
 <li>Shares of Boston Scientific declined 2.3% in early trading following the company’s announcement that it will be unable to achieve Q3 and full-year 2026 targets.</li>
 <li>The financial shortfall is directly attributed to the security breach that was initially identified on August 25.</li>
 <li>Management had earlier projected annual sales expansion of 5.5% to 6.5% alongside adjusted earnings per share ranging from $3.28 to $3.32.</li>
 <li>Year-to-date, BSX shares have declined 50%, with a 55% drop over the trailing twelve months, trading significantly below the 52-week peak of $109.50.</li>
 <li>While TD Cowen maintained its Buy recommendation with a $56 target price, the formal financial alert overshadowed this optimistic stance.</li>
</ul>
<a href="https://www.barrons.com/articles/boston-scientific-stock-earnings-guidance-cyberattack-bd0e8c0b?mod=RTA" rel="noopener noreferrer nofollow">Boston Scientific (BSX)</a> shares retreated 2.3% to $46.68 during premarket hours on Tuesday following the medical device manufacturer’s official announcement that it will be unable to meet previously issued financial targets for the third quarter and full fiscal year 2026.
<a href="https://knockoutstocks.com/stock/BSX" rel="noopener noreferrer nofollow"> <img src="https://knockoutstocks.com/api/stocks/BSX/embed" alt="BSX Stock Card"> Boston Scientific Corporation, BSX </a>
The revised outlook stems directly from the cybersecurity incident that the organization first revealed on August 25. In Tuesday’s regulatory disclosure, BSX stated it is “unlikely to meet” its projected revenue growth and adjusted earnings per share ranges for both the current quarter and the entire fiscal year.
This represents a more definitive position compared to the company’s earlier communications, when management indicated the financial consequences of the security breach remained undetermined.
Back in late July, Boston Scientific had established expectations for annual revenue expansion of 5.5% to 6.5% and adjusted earnings per share between $3.28 and $3.32. For the third quarter specifically, management projected revenue growth of 3% to 5% with adjusted earnings per share of 80 to 82 cents.
According to FactSet data, Wall Street analysts had been anticipating full-year adjusted earnings of $3.30 per share on revenue of $21.35 billion, with third-quarter consensus estimates at 81 cents per share and revenue of $5.26 billion.
The stock has experienced significant challenges throughout the year, even before this recent development. BSX has lost 50% of its value year-to-date and declined 55% over the past twelve months. Current trading levels sit far below the 52-week peak of $109.50, hovering closer to the 52-week bottom of $42.20.
<h3 id="analyst-reactions">Analyst Reactions</h3>
The withdrawal of financial guidance intensifies pressure on a stock already facing analyst concerns. Argus Research had earlier moved <a href="https://knockoutstocks.com/stock/BSX" rel="noopener noreferrer nofollow">BSX</a> from Buy to Hold, highlighting worries about expansion prospects for the Watchman product line and the domestic electrophysiology business segment.
Following second-quarter results and the initial cyber incident disclosure, Baird, JPMorgan, and Bank of America each reduced their price objectives for the stock.
TD Cowen stood out as the exception, maintaining its Buy rating alongside a $56 price target. The investment firm observed that by September 5, Boston Scientific’s primary distribution facilities were handling and dispatching products at or exceeding typical capacity levels. Despite this encouraging operational update, it provided minimal relief against Tuesday’s formal financial warning.
<h3 id="what-comes-next">What Comes Next</h3>
Boston Scientific indicated it has discovered no signs of continued unauthorized system access, although the inquiry remains ongoing.
Management noted that it anticipates recapturing a portion of the foregone revenue as business operations normalize, customer orders get processed, and order backlogs diminish.
The complete financial toll from the security incident has yet to be quantified. Boston Scientific intends to provide comprehensive details regarding its operational status and financial trajectory, including the cyberattack’s consequences, when it reports third-quarter results on October 28.
Fellow medical technology companies Abbott and Medtronic have similarly confronted cybersecurity challenges in 2026, contributing to sustained caution across the broader sector.
The post <a href="https://blockonomi.com/boston-scientific-bsx-stock-tumbles-as-cyberattack-forces-earnings-warning/" rel="noopener noreferrer nofollow">Boston Scientific (BSX) Stock Tumbles as Cyberattack Forces Earnings Warning</a> appeared first on <a href="https://blockonomi.com" rel="noopener noreferrer nofollow">Blockonomi</a>.

Boston Scientific (BSX) Stock Tumbles as Cyberattack Forces Earnings Warning

Table of Contents

Blockonomi

Other articles published on Sep 8, 2026

Join our free newsletter for daily crypto updates!